Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?
Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?
Pharma & Biotech
Pharma & Biotech
What Agenus’ BOT and BAL biomarker work reveals about rescuing immunologically cold tumors
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.
Pharma & Biotech
How Agenus is taking aim at cold tumors with Fc-enhanced anti-CTLA-4 therapy
Agenus sees 23% response rate in platinum-refractory ovarian cancer with BOT+BAL. Find out how this IO combo could reshape the treatment landscape.